retatrutide weight loss trial Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 weeks in all doses in the Retatrutide FDA Approval Status 2026:
Pay in 4 interest-free payments of $7.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10












/product/51/4175523/1.jpg?8625)













